Literature DB >> 15654060

Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis.

M A S D Lima, R B S Bica, A Q C Araújo.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15654060      PMCID： PMC1739477          DOI： 10.1136/jnnp.2004.035709

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  9 in total

1.  SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.

Authors:  Vanessa Adaui; Kristien Verdonck; Iván Best; Elsa González; Martín Tipismana; Jorge Arévalo; Guido Vanham; Miguel Campos; Mirko Zimic; Eduardo Gotuzzo
Journal:  J Neurovirol       Date:  2006-12       Impact factor: 2.643

2.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

3.  Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Kelen Cristina Ribeiro Malmegrim de Farias; Alessandra De Paula Sousa; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-16       Impact factor: 2.205

4.  Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses.

Authors:  Georgina Ireland; Sara Croxford; Jennifer Tosswill; Rajani Raghu; Katy Davison; Patricia Hewitt; Ruth Simmons; Graham Taylor
Journal:  Euro Surveill       Date:  2017-05-18

5.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

Review 6.  Human T-cell lymphotropic virus (HTLV)-associated encephalopathy: an under-recognised cause of acute encephalitis? Case series and literature review.

Authors:  Ania A Crawshaw; Divya Dhasmana; Brynmor Jones; Carolyn M Gabriel; Steve Sturman; Nicholas W S Davies; Graham P Taylor
Journal:  J Neurol       Date:  2018-02-08       Impact factor: 4.849

7.  Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.

Authors:  Flávia Dos Santos Souza; Nicole Lardini Freitas; Yago Côrtes Pinheiro Gomes; Rafael Carvalho Torres; Juliana Echevarria-Lima; Isaac Lima da Silva-Filho; Ana Claudia Celestino Bezerra Leite; Marco Antonio Sales Dantas de Lima; Marcus Tulius Teixeira da Silva; Abelardo de Queiroz Campos Araújo; Otávio Melo Espíndola
Journal:  Front Immunol       Date:  2021-10-26       Impact factor: 7.561

Review 8.  Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease.

Authors:  Veronique Lepoutre; Pooja Jain; Kevin Quann; Brian Wigdahl; Zafar K Khan
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

9.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Authors:  Soraya Maria Menezes; Daniele Decanine; David Brassat; Ricardo Khouri; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Anne-Mieke Vandamme; Bernardo Galvão-Castro; Roland Liblau; Johan Van Weyenbergh
Journal:  J Neuroinflammation       Date:  2014-01-29       Impact factor: 8.322
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.